Zobrazeno 1 - 10
of 193
pro vyhledávání: '"Teiji, Kuzuya"'
Autor:
Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4225-4240 (2024)
The relationship between antitumor response and tumor marker changes was evaluated in patients with advanced hepatocellular carcinoma treated with durvalumab plus tremelimumab (Dur/Tre). Forty patients were enrolled in this retrospective evaluation o
Externí odkaz:
https://doaj.org/article/2b449c6a49b64eebb72209e1b4056043
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Publikováno v:
Liver Cancer (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, th
Externí odkaz:
https://doaj.org/article/48f623fe69374965a18cf38cb68f57fa
Autor:
Kazunori Nakaoka, Senju Hashimoto, Naoto Kawabe, Teiji Kuzuya, Hiroyuki Tanaka, Takuji Nakano, Yuichiro Uchida, Yohei Miyachi, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Takeshi Takahara, Ryoji Miyahara, Tomoyuki Shibata, Tetsuya Tsukamoto, Koichi Suda, Yoshiki Hirooka
Publikováno v:
DEN Open, Vol 3, Iss 1, Pp n/a-n/a (2023)
Abstract The diagnosis of bile duct tumors can be difficult at times. A transpapillary bile duct biopsy findings with endoscopic retrograde cholangiopancreatography sometimes contradict diagnostic imaging findings. In bile duct tumors, inflammatory p
Externí odkaz:
https://doaj.org/article/80a675cda78645cc901f1ef00cd3205b
Autor:
Takashi Honda, Masatoshi Ishigami, Kenta Yamamoto, Tomoaki Takeyama, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Masanao Nakamura, Hiroki Kawashima, Ryoji Miyahara, Tetsuya Ishikawa, Yoshiki Hirooka, Mitsuhiro Fujishiro
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract The gut microbiota interacts with infectious diseases and affects host immunity. Liver disease is also reportedly associated with changes in the gut microbiota. To elucidate the changes in the gut microbiota before and after hepatitis C viru
Externí odkaz:
https://doaj.org/article/fa82174961934fa0b1a558f9c1e3ace3
Autor:
Teiji Kuzuya, Naoto Kawabe, Mizuki Ariga, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Takeshi Takahara, Yutaro Kato, Yoshiki Hirooka
Publikováno v:
Cancers, Vol 15, Iss 11, p 2952 (2023)
(1) Background: This study aimed to investigate clinical outcomes for cabozantinib in clinical practice in patients with advanced hepatocellular carcinoma (HCC) previously treated with atezolizumab plus bevacizumab (Atz/Bev), with a focus on whether
Externí odkaz:
https://doaj.org/article/640787a5c1a745228c599a98797a2034
Autor:
Kazuyuki Mizuno, Norihiro Imai, Takafumi Yamamoto, Shinya Yokoyama, Kenta Yamamoto, Takanori Ito, Yoji Ishizu, Takashi Honda, Teiji Kuzuya, Masatoshi Ishigami, Hiroki Kawashima
Publikováno v:
Cancers, Vol 15, Iss 10, p 2853 (2023)
Background: Proteinuria is a common adverse event in systemic therapy for hepatocellular carcinoma (HCC). However, whether the presence of pretreatment proteinuria affects the clinical course is still unclear. Method: From 2011 to 2022, 321 patients
Externí odkaz:
https://doaj.org/article/fde9ecf95f8d44e9bee6559a6e1fd832
Autor:
Hiroyuki Tanaka, Hiroki Kawashima, Eizaburo Ohno, Takuya Ishikawa, Tadashi Iida, Eri Ishikawa, Kazuhiro Furukawa, Masanao Nakamura, Takashi Honda, Yoshie Shimoyama, Ryoji Miyahara, Naoto Kawabe, Teiji Kuzuya, Senju Hashimoto, Masatoshi Ishigami, Yoshiki Hirooka, Mitsuhiro Fujishiro
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Endoscopic papillectomy of duodenal papillary tumors (PT) is indicated for adenomas or well-differentiated adenocarcinomas that do not involve the sphincter of Oddi. However, there is currently no reliable pre-operative method to
Externí odkaz:
https://doaj.org/article/da493f6b541d46cf914be2f053829206
Autor:
Takashi Honda, Norie Yamada, Asako Murayama, Masaaki Shiina, Hussein Hassan Aly, Asuka Kato, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Masatoshi Ishigami, Yoshiki Murakami, Tomohisa Tanaka, Kohji Moriishi, Hironori Nishitsuji, Kunitada Shimotohno, Tetsuya Ishikawa, Mitsuhiro Fujishiro, Masamichi Muramatsu, Takaji Wakita, Takanobu Kato
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 5, Pp 1583-1598 (2021)
Background & Aims: To provide an adequate treatment strategy for chronic hepatitis B, it is essential to know which patients are expected to have a good prognosis and which patients do not require therapeutic intervention. Previously, we identified t
Externí odkaz:
https://doaj.org/article/936b7d4f3a05426180767516fa5fb8ee
Autor:
Kazunori Nakaoka, Eizaburo Ohno, Naoto Kawabe, Teiji Kuzuya, Kohei Funasaka, Yoshihito Nakagawa, Mitsuo Nagasaka, Takuya Ishikawa, Ayako Watanabe, Takumi Tochio, Ryoji Miyahara, Tomoyuki Shibata, Hiroki Kawashima, Senju Hashimoto, Yoshiki Hirooka
Publikováno v:
Diagnostics, Vol 13, Iss 2, p 215 (2023)
Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is su
Externí odkaz:
https://doaj.org/article/12bb2fdd80b142b1b7e681d1637996f0
Autor:
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Akiko Wakuta, Ayano Oonishi, Teiji Kuzuya, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Ei Itobayashi, Toru Ishikawa, Koichi Takaguchi, Akemi Tsutsui, Noritomo Shimada, Masatoshi Kudo, Takashi Kumada
Publikováno v:
Liver Cancer, Vol 9, Iss 6, Pp 734-743 (2020)
Introduction: The ALBI score is acknowledged as the gold standard for the assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and tota
Externí odkaz:
https://doaj.org/article/4ed22cb7f09b4315bfa482946d2d0f82